Table 5.
ICI-induced immune-related adverse drug reactions reported in the Campania Region and collected into the RNF.
| TOXICITY TYPEs | irADRs N=132 |
ICIs | |||
|---|---|---|---|---|---|
| Nivolumab | Ipilimumab | Pembrolizumab | Atezolizumab | ||
| N=85 | N=34 | N=12 | N=1 | ||
| Skin Toxicity | 49 (37.1%) | 30 (35.3%) | 12 (35.3%) | 7 (58.3%) | – |
| Itch | 32 | 15 | 12 | 5 | |
| Psoriasis | 6 | 6 | – | – | |
| Macular-papular rash | 4 | 4 | – | – | |
| Vitiligo | 3 | 3 | – | – | |
| Epidermolysis bullosa | 2 | – | – | 2 | |
| Pemphigus | 2 | 2 | – | – | |
| Gastrointestinal toxicity | 32 (24.2%) | 14 (16.5%) | 17 (50%) | 1 (8.3%) | – |
| Diarrhea | 24 | 9 | 14 | 1 | |
| Enterocolitis | 4 | 1 | 3 | – | |
| Pancreatitis | 4 | 4 | – | – | |
| Endocrine toxicity | 22 (16.7%) | 19 (22.4%) | – | 2 (16.7%) | 1 (100%) |
| Hypothyroidism | 13 | 11 | 2 | – | |
| Hypophysitis | 3 | 3 | – | – | |
| Thyroiditis | 3 | 3 | – | – | |
| Hyperthyroidism | 2 | 2 | – | – | |
| Thyrotoxicosis | 1 | – | – | 1 | |
| Pulmonary toxicity | 9 (6.8%) | 6 (7.1%) | 1 (2.9%) | 2 (16.7%) | – |
| Pneumonia | 8 | 6 | 1 | 1 | |
| Respiratory failure | 1 | – | – | 1 | |
| Hematological toxicity | 7 (%) | 5 (5.8%) | 2 (5.9%) | – | – |
| Thrombocytopenia | 6 | 5 | 1 | ||
| Neutropenia | 1 | – | 1 | ||
| Liver toxicity | 5 (3.8%) | 3 (3.5%) | 2 (5.9%) | – | – |
| Hepatitis | 5 | 3 | 2 | ||
| Musculoskeletal toxicity | 3 (2.3%) | 3 (3.5%) | – | ||
| Myositis | 2 | 2 | |||
| Arthritis | 1 | 1 | |||
| Central toxicity | 3 (2.3%) | 3 (3.5%) | – | – | – |
| Neuropathy | 1 | 1 | |||
| Encephalitis | 1 | 1 | |||
| Myasthenia | 1 | 1 | |||
| Ocular toxicity | 1 (0.8%) | 1 (1.2%) | – | – | – |
| Uveitis | 1 | 1 | |||
| Renal toxicity | 1 (0.8%) | 1 (1.2%) | – | – | – |
| Nephritis | 1 | 1 | |||